Investors Buy High Volume of Amneal Pharmaceuticals Call Options (NASDAQ:AMRX)

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) was the recipient of unusually large options trading on Monday. Investors purchased 2,563 call options on the stock. This represents an increase of 719% compared to the average volume of 313 call options.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX traded down $0.05 on Monday, hitting $7.73. The company’s stock had a trading volume of 72,130 shares, compared to its average volume of 1,376,732. The company has a market capitalization of $2.40 billion, a price-to-earnings ratio of -11.37 and a beta of 1.12. Amneal Pharmaceuticals has a 12 month low of $5.01 and a 12 month high of $9.48. The stock’s 50-day moving average is $8.42 and its two-hundred day moving average is $7.94.

Insider Buying and Selling

In related news, SVP Jason B. Daly sold 43,657 shares of the business’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the completion of the sale, the senior vice president now owns 13,665 shares of the company’s stock, valued at $117,655.65. This represents a 76.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 26.56% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of AMRX. Rothschild Investment LLC acquired a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth approximately $26,000. Gladius Capital Management LP acquired a new stake in Amneal Pharmaceuticals in the third quarter worth approximately $37,000. DekaBank Deutsche Girozentrale bought a new position in Amneal Pharmaceuticals during the 2nd quarter valued at $42,000. nVerses Capital LLC bought a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth $62,000. Finally, Xponance Inc. bought a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth $65,000. Institutional investors own 31.82% of the company’s stock.

Analyst Ratings Changes

AMRX has been the topic of a number of research reports. Truist Financial increased their price target on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, October 2nd. Piper Sandler increased their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target for the company in a report on Friday, September 6th. Finally, StockNews.com cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Amneal Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.